SMC Radiation Oncology SABR Cohort for Oligometastasis

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 18 years and older
• All sexes
• No healthy volunteers
• Adult, Older adult

Study population: Cancer patients who are Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

About this study

Official title: Cohort Study for Local Stereotactic Body Radiotherapy in Patients With Oligometastatic or Oligoprogressive Cancer

Conditions

Stereotactic Body Radiation Therapy (SBRT), Oligometastasis, Oligoprogression, ctDNA, Patient-Reported Outcomes (PRO)

Being tested

Stereotactic body radiotherapy (SBRT)

Keywords

Stereotactic body radiotherapy, Oligometastasis, Oligoprogression, ctDNA

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• Stereotactic body radiotherapy (SBRT)Radiation

  Stereotactic body radiotherapy (SABR) using photon or proton beams will be delivered per standard practice (1-5 fractions).

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Progression-free survival

   Time from the start of stereotactic body radiotherapy (SABR) to the first documented event of local failure, distant failure, death from any cause, or last follow-up, whichever occurs first.

   Measured: From start of SABR to the earliest of local failure, distant failure, death, or last follow-up. It will be measured at 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.

2. Physician assessed toxicity

   Evaluated by treating physician based on CTCAE ver 5.0

   Measured: 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.

3. Patient-reported outcome

   It will be measured by PRO-CTCAE coreset 12.

   Measured: 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.

4. Local failure

   Local regrowth or progression at the site of SABR.

   Measured: 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.

5. Dynamics of ctDNA

   ctDNA analysis

   Measured: It will be collected 1-week before SABR and 4-6 weeks after SABR.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted13 Aug 2025
2. Study start1 May 2025
3. Primary completion31 Dec 2027 (estimated)
4. Study completion31 Mar 2030 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for Stereotactic Body Radiation Therapy (SBRT)Studies of the same condition, open and under way.
• More trials run by Samsung Medical CenterThe sponsor's other registered studies.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.